Biocryst Pharmaceuticals (BCRX) 10.06 $BCRX
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Valuable Updates on Pharmaceutical Companies: New Research on Avalanche Biotechnologies, BioCryst, Biogen, Biota Pharmaceuticals, and Bio-Techne
PR Newswire - Tue Feb 10, 7:30AM CST
Editor Note: For more information about this release, please scroll to bottom.
BIIB: 391.66 (-0.45), BCRX: 10.06 (-0.09), BOTA: 2.60 (-0.06), TECH: 94.61 (+1.83), AAVL: 36.29 (+0.01)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 4:37PM CST
FLIR: 33.01 (-0.23), ETR: 79.12 (-1.53), BCRX: 10.06 (-0.09), MCK: 224.89 (+0.12), HCN: 77.12 (-0.33), QUIK: 2.17 (+0.01), WAC: 20.29 (+2.57), RUSS: 11.59 (-0.81), ENTA: 33.30 (-0.44), LPI: 13.25 (+0.81)
BioCryst to Announce 2014 Financial Results February 18 & Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 1:18PM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its fourth quarter 2014 financial results will be released on Wednesday, February 18, 2015. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab, II, Senior Vice President & Chief Financial Officer, Dr. William P. Sheridan, Senior Vice President & Chief Medical Officer and Lynne Powell, Senior Vice President & Chief Commercial Officer.
BCRX: 10.06 (-0.09)
Merck KGaA, Precision Biologics to Develop Cancer Antibody - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:46PM CST
Merck KGaA's (MKGAF) Life Science business, Merck Millipore announced an agreement with Texas-based Precision Biologics, Inc. for providing upstream process development services to the company for the advancement of a preclinical monoclonal antibody, NEO-201.
BCRX: 10.06 (-0.09), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
3 Biotechs Looking Good this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 11:38AM CST
A number of biotech companies are seeing improvements in their financial results.
BCRX: 10.06 (-0.09), PCYC: 163.28 (+0.23), ARIA: 7.35 (+0.45)
Earnings Peek: BioCryst Pharmaceuticals Likely To Beat Estimates
Clinically Sound Investor - at Seeking Alpha - Tue Jan 27, 4:35PM CST
BCRX: 10.06 (-0.09)
BioCryst Pharmaceuticals awarded US FDA's Fast Track designation for BCX4161 for hereditary angioedema
M2 - Tue Jan 27, 3:22AM CST
Biotechnology company BioCryst Pharmaceuticals (NasdaqGS:BCRX) reported on Monday the receipt of the US Food and Drug Administration's (FDA) Fast Track designation for BCX4161 for the treatment of hereditary angioedema.
BCRX: 10.06 (-0.09)
BioCryst HA candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 6:49AM CST
BCRX: 10.06 (-0.09)
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema
GlobeNewswire - Mon Jan 26, 5:58AM CST
BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical development for the treatment of hereditary angioedema.
BCRX: 10.06 (-0.09)
Strength Seen in Egalet (EGLT): Stock Soars 23.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 8:25AM CST
Egalet (EGLT) was a big mover last session, with its shares surging almost 24% on the day.
BCRX: 10.06 (-0.09), EGLT: 10.60 (+0.58)
UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 6:00PM CST
UCB S.A. (UCBJF) announced that its investigational antiepileptic candidate, brivaracetam, has been accepted for review in the U.S. and the EU.
BCRX: 10.06 (-0.09), AMGN: 153.48 (+0.30), BIOD: 1.38 (-0.14)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
Flamel Technologies (FLML) in Focus: Stock Gains 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 8:25AM CST
Flamel Technologies (FLML) was a big mover last session, with shares rising over 15% on the day.
BCRX: 10.06 (-0.09), FLML: 14.15 (+0.15)
BioCryst's BCX4161 Recommended for Orphan Drug in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 1:00PM CST
BioCryst Pharmaceuticals, Inc. (BCRX) received a positive opinion regarding its application for orphan drug status for BCX4161 in the EU.
ENDP: 84.01 (+1.12), BCRX: 10.06 (-0.09), SHPG: 239.82 (+6.11), AUXL: 36.47 (-0.06)
Pharmacyclics (PCYC) Looks Good: Stock Moves 16.4% Up - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 7:51AM CST
Pharmacyclics Inc. (PCYC) was a big mover last session, as its shares rose over 16% on the day.
BCRX: 10.06 (-0.09), PCYC: 163.28 (+0.23)
BioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema
GlobeNewswire - Wed Jan 14, 6:42AM CST
BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) issued a positive opinion on the application for orphan drug designation for BCX4161 for the treatment of patients with hereditary angioedema (HAE). The European Commission will make a final decision on European Orphan Drug Designation based upon the COMP positive opinion. On December 23, 2014, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for BCX4161.
BCRX: 10.06 (-0.09)
COMP supports Orphan Drug tag for BioCryst HAE candidate
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 6:31AM CST
BCRX: 10.06 (-0.09)
BioCryst to Present at J.P. Morgan Healthcare Conference
GlobeNewswire - Tue Jan 06, 5:50AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at the 33 annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2015 at 9:00 a.m. Pacific Time.
BCRX: 10.06 (-0.09), JPM: 59.67 (+0.10)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Valuable Updates on Pharmaceutical Companies: New Research on Avalanche Biotechnologies, BioCryst, Biogen, Biota Pharmaceuticals, and Bio-Techne
PR Newswire - Tue Feb 10, 7:30AM CST
Editor Note: For more information about this release, please scroll to bottom.
BIIB: 391.66 (-0.45), BCRX: 10.06 (-0.09), BOTA: 2.60 (-0.06), TECH: 94.61 (+1.83), AAVL: 36.29 (+0.01)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 4:37PM CST
FLIR: 33.01 (-0.23), ETR: 79.12 (-1.53), BCRX: 10.06 (-0.09), MCK: 224.89 (+0.12), HCN: 77.12 (-0.33), QUIK: 2.17 (+0.01), WAC: 20.29 (+2.57), RUSS: 11.59 (-0.81), ENTA: 33.30 (-0.44), LPI: 13.25 (+0.81)
BioCryst to Announce 2014 Financial Results February 18 & Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 1:18PM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its fourth quarter 2014 financial results will be released on Wednesday, February 18, 2015. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab, II, Senior Vice President & Chief Financial Officer, Dr. William P. Sheridan, Senior Vice President & Chief Medical Officer and Lynne Powell, Senior Vice President & Chief Commercial Officer.
BCRX: 10.06 (-0.09)
Merck KGaA, Precision Biologics to Develop Cancer Antibody - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:46PM CST
Merck KGaA's (MKGAF) Life Science business, Merck Millipore announced an agreement with Texas-based Precision Biologics, Inc. for providing upstream process development services to the company for the advancement of a preclinical monoclonal antibody, NEO-201.
BCRX: 10.06 (-0.09), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
3 Biotechs Looking Good this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 11:38AM CST
A number of biotech companies are seeing improvements in their financial results.
BCRX: 10.06 (-0.09), PCYC: 163.28 (+0.23), ARIA: 7.35 (+0.45)
Earnings Peek: BioCryst Pharmaceuticals Likely To Beat Estimates
Clinically Sound Investor - at Seeking Alpha - Tue Jan 27, 4:35PM CST
BCRX: 10.06 (-0.09)
BioCryst Pharmaceuticals awarded US FDA's Fast Track designation for BCX4161 for hereditary angioedema
M2 - Tue Jan 27, 3:22AM CST
Biotechnology company BioCryst Pharmaceuticals (NasdaqGS:BCRX) reported on Monday the receipt of the US Food and Drug Administration's (FDA) Fast Track designation for BCX4161 for the treatment of hereditary angioedema.
BCRX: 10.06 (-0.09)
BioCryst HA candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 6:49AM CST
BCRX: 10.06 (-0.09)
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema
GlobeNewswire - Mon Jan 26, 5:58AM CST
BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical development for the treatment of hereditary angioedema.
BCRX: 10.06 (-0.09)
Strength Seen in Egalet (EGLT): Stock Soars 23.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 8:25AM CST
Egalet (EGLT) was a big mover last session, with its shares surging almost 24% on the day.
BCRX: 10.06 (-0.09), EGLT: 10.60 (+0.58)
UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 6:00PM CST
UCB S.A. (UCBJF) announced that its investigational antiepileptic candidate, brivaracetam, has been accepted for review in the U.S. and the EU.
BCRX: 10.06 (-0.09), AMGN: 153.48 (+0.30), BIOD: 1.38 (-0.14)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
Flamel Technologies (FLML) in Focus: Stock Gains 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 8:25AM CST
Flamel Technologies (FLML) was a big mover last session, with shares rising over 15% on the day.
BCRX: 10.06 (-0.09), FLML: 14.15 (+0.15)
BioCryst's BCX4161 Recommended for Orphan Drug in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 1:00PM CST
BioCryst Pharmaceuticals, Inc. (BCRX) received a positive opinion regarding its application for orphan drug status for BCX4161 in the EU.
ENDP: 84.01 (+1.12), BCRX: 10.06 (-0.09), SHPG: 239.82 (+6.11), AUXL: 36.47 (-0.06)
Pharmacyclics (PCYC) Looks Good: Stock Moves 16.4% Up - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 7:51AM CST
Pharmacyclics Inc. (PCYC) was a big mover last session, as its shares rose over 16% on the day.
BCRX: 10.06 (-0.09), PCYC: 163.28 (+0.23)
BioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema
GlobeNewswire - Wed Jan 14, 6:42AM CST
BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) issued a positive opinion on the application for orphan drug designation for BCX4161 for the treatment of patients with hereditary angioedema (HAE). The European Commission will make a final decision on European Orphan Drug Designation based upon the COMP positive opinion. On December 23, 2014, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for BCX4161.
BCRX: 10.06 (-0.09)
COMP supports Orphan Drug tag for BioCryst HAE candidate
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 6:31AM CST
BCRX: 10.06 (-0.09)
BioCryst to Present at J.P. Morgan Healthcare Conference
GlobeNewswire - Tue Jan 06, 5:50AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at the 33 annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2015 at 9:00 a.m. Pacific Time.
BCRX: 10.06 (-0.09), JPM: 59.67 (+0.10)
